Locally advanced squamous cell carcinoma of the cervix treated with definitive radiotherapy
Conditions
Interventions
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed primary cervical cancer, with histological types including squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma. 2. Clinical stage IB3, II, III or IVA according to the 2018 FIGO staging system; no prior history of surgery, radiotherapy, chemotherapy, immunotherapy or other systemic anti-tumor treatment. 3. Received definitive concurrent chemoradiotherapy at Zhejiang Cancer Hospital, Sichuan Cancer Hospital, or the Affiliated Hospital of Southwest Medical University. The treatment regimen consisted of external beam radiotherapy, brachytherapy, and platinum-based concurrent chemotherapy. 4. Pelvic magnetic resonance imaging completed within 2 weeks before the initiation of radiotherapy, with complete imaging data available for analysis. 5. Cervical biopsy specimens obtained prior to radiotherapy, with analyzable whole-slide digital pathological H&E images available. 6. Complete baseline clinical data, laboratory data, treatment records and follow-up data. 7. Follow-up duration of no less than 24 months, or occurrence of a study endpoint within 24 months.
Exclusion criteria
Exclusion criteria: 1. Prior pelvic radiotherapy, pelvic tumor surgery, or any other anti-tumor treatment for cervical cancer. 2. Presence of a second primary malignant tumor, or suspected dual/multiple primary malignancies that cannot be ruled out. 3. Lack of pathological confirmation before radiotherapy, or poor-quality digital pathological images unsuitable for analysis. 4. Severe artifacts, missing key sequences on pelvic MRI, or images that do not meet the requirements for radiological analysis. 5. Severe missing data of radiotherapy plans, dosimetric parameters or concurrent chemotherapy records, making collection of key variables impossible. 6. Underwent curative or debulking surgery within 6 months after concurrent chemoradiotherapy, which may significantly affect the assessment of the primary endpoint. 7. Severe loss to follow-up or unreliable determination of study endpoints. 8. Any other conditions deemed inappropriate for enrollment in this study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hand-engineered radiomic features; | — |
Countries
China
Contacts
Public ContactZhuomin Yin
Zhejiang Cancer Hospital
Outcome results
None listed